- Teleflex (TFX, Financial) will present multiple clinical studies at the 2025 American Urological Association Annual Meeting.
- The studies focus on benign prostatic hyperplasia (BPH) treatment and rectal spacing for prostate cancer radiation therapy.
- Teleflex will host educational sessions including a Prostate Health Symposium at Allegiant Stadium.
Teleflex Incorporated (TFX), a leading global provider of medical technologies, is set to showcase its latest clinical research and provide educational sessions at the 2025 American Urological Association (AUA) Annual Meeting. The event will take place in Las Vegas from April 26-29, 2025.
Key studies to be presented include the CLEAR Randomized Controlled Trial comparing UroLift™ PUL with Rezum WVTT, and the IMPACT trial evaluating UroLift™ PUL against medication for treating benign prostatic hyperplasia (BPH). In addition, research on the safety of stabilized hyaluronic acid as a rectal spacer will be highlighted.
Teleflex (TFX, Financial) will also host several educational events during the meeting. These include a Semi-Live Barrigel Case Review, an advanced practice provider (APP) educational breakfast on efficient urology practice, and a Prostate Health Symposium at Allegiant Stadium. Daily presentations at Teleflex booth 1401 will feature discussions on the Barrigel™ rectal spacer and UroLift™ System.
The UroLift™ System is a minimally invasive treatment designed for lower urinary tract symptoms caused by benign prostatic hyperplasia, while the Barrigel™ rectal spacer aids in reducing side effects during prostate cancer radiation therapy by separating the prostate from the rectum.
These initiatives reflect Teleflex's commitment to advancing evidence-based innovations in medical technologies, aiming to enhance patient outcomes in urological healthcare. For more information about the UroLift System and Barrigel Rectal Spacer, interested parties can visit the respective websites.
